Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy.
Radioiodinated metaiodobenzylguanidine [(131)I-MIBG] is commonly used to treat resistant neuroblastoma or metastatic pheochromocytoma [MP] with little non-hematopoietic toxicity. We describe here transient sialoadenitis, a previously unreported complication. Ten patients [9 neuroblastoma and 1 MP] received 12-18 mCi/kg of (131)I-MIBG. Five patients had bilateral parotid swelling, two with associated buccal discomfort within 24 hr of injection which subsided within 48 hr. Grade 3 or 4 serum amylase elevation was documented in 8/8 patients tested [median 1,336; range: 576-8,830 U/L] which normalized [25-125 U/L] within 4-14 [median 5.5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia.
Modak
Shakeel
S
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. modaks@mskcc.org
Pandit-Taskar
Neeta
N
Kushner
Brian H
BH
Kramer
Kim
K
Smith-Jones
Peter
P
Larson
Steven
S
Cheung
Nai-Kong V
NK
D019797:3-Iodobenzylguanidine / Q000009:adverse effects* / Q000627:therapeutic use; D000293:Adolescent; D000681:Amylases / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D009447:Neuroblastoma / Q000532:radiotherapy; D010673:Pheochromocytoma / Q000532:radiotherapy / Q000556:secondary; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use; D012793:Sialadenitis / Q000209:etiology*
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D000681:Amylases